Role of Ribavirin in the Era of Direct-Acting Antiviral Therapies of Chronic Hepatitis C
| Autor: | Mohamed Rady, Omkolsoum M Alhaddad, Nashwa Shebl, Maha M. Elsabaawy, Ahmed Wahb, Alyaa Sabry, Fatma O. Khalil, Helmy Elshazly, Dalia M Elsabaawy |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Microbiology (medical) Adult Liver Cirrhosis Male Sofosbuvir 030106 microbiology Microbiology Antiviral Agents Cohort Studies 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Chronic hepatitis Virology Ribavirin Medicine Humans 030212 general & internal medicine Aged Retrospective Studies business.industry virus diseases Hepatitis C Chronic Middle Aged digestive system diseases Liver Transplantation Infectious Diseases chemistry Hcv treatment Drug Therapy Combination Egypt Female business Direct acting medicine.drug |
| Zdroj: | Expert review of anti-infective therapy. 18(8) |
| ISSN: | 1744-8336 |
| Popis: | The efficacy of adding ribavirin (RBV) to direct antivirals (DAAs) in HCV treatment is still debatable, with allegations of insecure profiles.To evaluate safety and efficacy of RBV in the era of DAAs in chronic HCV Egyptian patients.In this cohort retrospective study, data of 847 HCV patients treated with different regimens of DAAs with or without RBV were recruited between June 2017 and September 2018. Cases were categorized into five groups: non-cirrhotic (318), compensated (196), decompensated liver cirrhosis (53), post liver transplantation (30), and 250 treatment experienced patients. All patients' demographics and laboratory characteristics were evaluated at baseline, week |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|